Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center, reviews the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis. They also discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Gain practical insights into the HER2 IHC scoring criteria. We will examine stained slides to refine the participant’s ability to apply guidelines with confidence and consistency and learn how to standardize these findings in pathology reports to facilitate high-level multidisciplinary discussions and guide precision treatment decisions.
This on-demand webinar was originally broadcast on October 20, 2026.
What will this webinar empower you to do?
• Understand the biological spectrum of HER2 protein expression.
• Examine and score HER2 IHC slides accurately using updated ASCO-CAP guidelines scoring criteria.
• Integrate HER2-low and HER2-ultra-low classifications into pathology reports to facilitate collaborative treatment decisions between pathologists and oncologists.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY.
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.